BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/20/2024 3:53:47 AM | Browse: 158 | Download: 863
 |
Received |
|
2024-04-04 06:41 |
|
Peer-Review Started |
|
2024-04-04 06:41 |
|
First Decision by Editorial Office Director |
|
2024-08-01 21:54 |
|
Return for Revision |
|
2024-08-01 21:54 |
|
Revised |
|
2024-08-30 08:18 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-09-12 02:40 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-09-12 03:34 |
|
Articles in Press |
|
2024-09-12 03:34 |
|
Edit the Manuscript by Language Editor |
|
2024-12-02 13:41 |
|
Typeset the Manuscript |
|
2024-12-12 07:58 |
|
Publish the Manuscript Online |
|
2024-12-20 03:53 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
In silico analysis of lncRNA-miRNA-mRNA signatures related to sorafenib effectiveness in liver cancer cells
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Patricia de la Cruz-Ojeda, Ester Parras-Martínez, Raquel Rey-Pérez and Jordi Muntané |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Instituto de Salud Carlos III (ISCiii) |
PI19/01266 and PI22/00857 |
| Consejería de Salud y Familias (Junta de Andalucía) |
PI-0216-2020 and PIP-0215-2020 |
| Biomedical Research Network Center for Liver and Digestive Diseases (CIBERehd) founded by the ISCIII and co-financed by European Regional Development Fund “A way to achieve Europe” ERDF |
|
|
| Corresponding Author |
Jordi Muntané, PhD, Research Associate, Department of Oncology Surgery, Cell Therapy and Organ Transplantation, Institute of Biomedicine of Seville, Virgen del Rocio University Hospital, Avn. Manuel Siurot S/N, Seville 41013, Spain. jmuntane-ibis@us.es |
| Key Words |
Cell culture; Hepatocellular carcinoma; Non-coding RNA; RNAseq; Sorafenib |
| Core Tip |
In the current study, we investigated the differential lncRNA-miRNA-mRNA regulatory axes in HepG2 and SNU449 under Sorafenib treatment. The study identified lncRNA-miRNA regulatory axes leading to increased expression mRNA with positive (SMAD7, TIRARP, TFAP4, FAXDC2 and ADRB2) and negative (VEGFA) therapeutic effects in HepG2 and SNU449 under Sorafenib treatment. |
| Publish Date |
2024-12-20 03:53 |
| Citation |
de la Cruz-Ojeda P, Parras-Martínez E, Rey-Pérez R, Muntané J. In silico analysis of lncRNA-miRNA-mRNA signatures related to sorafenib effectiveness in liver cancer cells. World J Gastroenterol 2025; 31(3): 95207 |
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i3/95207.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i3.95207 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
